A Phase I Study of T900607 given once every three weeks in patients with advanced refractory cancer.

Trial Profile

A Phase I Study of T900607 given once every three weeks in patients with advanced refractory cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2014

At a glance

  • Drugs T 900607 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top